What question did this study set out to answer?

This study investigates the effects of deferasirox on neutrophil activation and extracellular trap formation.

Iron‐chelating agent, deferasirox, inhibits neutrophil activation and extracellular trap formation

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial demonstrates that deferasirox inhibits neutrophil activation and extracellular trap formation, suggesting protective effects.

This study investigates the effects of deferasirox on neutrophil activation and extracellular trap formation.
Human neutrophils were isolated and treated with deferasirox (DFS) followed by stimulation with PMA or fMLP.
Vacuole formation was analyzed using electron microscopy and NET formation was assessed with immunohistological methods and dsDNA quantification.
DFS concentrations ranged from 5-100 μmol/L to evaluate dose-dependent effects.
DFS (50 μmol/L) significantly inhibited vacuole formation in neutrophils.
The agent reduced NET formation, evidenced by lower dsDNA release, irrespective of the concentration.
DFS demonstrates protective effects against NET-related adverse outcomes, such as acute lung injury and thrombosis.

Kono et al. (2016) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial demonstrates that deferasirox inhibits neutrophil activation and extracellular trap formation, suggesting protective effects.